We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Uptravi

News List

Uptravi (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH) drugs
August 02, 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the FDA has approved Uptravi (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO
Janssen's UPTRAVI IV FDA-Approved for PAH contractpharma
August 02, 2021
New therapeutic option allows patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy.
NHS England to fund Actelion's Uptravi pharmatimes
January 03, 2019
Actelion has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH) can now be treated with Uptravi (selexipag).
PAH patients in England denied access to Actelion’s Uptravi on NHS pharmatimes
July 10, 2018
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Disappointment for Scottish patients with PAH as SMC says ‘no’ to Uptravi cphi-online
July 13, 2017
Selexipag is an innovative, oral treatment that specifically targets the prostacyclin pathway.